The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase II study of rucaparib in patients with high genomic LOH and/or BRCA 1/2 mutated stage IV non-small cell lung cancer (Lung-MAP Sub-Study, S1900A).
 
Jonathan W. Riess
Consulting or Advisory Role - Blueprint Medicines; Boehringer Ingelheim; Daiichi Sankyo; EcoR1 Capital; EMD Serono; Genentech; Medtronic; Novartis; Teladoc
Research Funding - AstraZeneca/MedImmune (Inst); Boehringer Ingelheim (Inst); GlaxoSmithKline (Inst); Merck (Inst); Novartis (Inst); Revolution Medicines (Inst); Spectrum Pharmaceuticals (Inst)
 
Mary Weber Redman
Consulting or Advisory Role - AstraZeneca
 
Paul Wheatley-Price
Honoraria - AstraZeneca; Bayer; Merck; Pfizer; Takeda
Consulting or Advisory Role - AstraZeneca; Bayer; Bristol-Myers Squibb; EMD Serono; Merck; Novartis; Pfizer; Roche Canada
Research Funding - Bristol-Myers Squibb (Inst); Pfizer (Inst); Roche Canada (Inst)
 
Bryan A. Faller
Consulting or Advisory Role - LEK
Travel, Accommodations, Expenses - Amgen; AstraZeneca; Boehringer Ingelheim; Celgene; EB SQUIBB; Eisai; Genentech; Lilly; Merck; Novartis; Takeda
 
Liza C. Villaruz
Consulting or Advisory Role - Achilles Therapeutics; Daiichi Sankyo/Astra Zeneca; Takeda
Research Funding - AstraZeneca (Inst); BMS (Inst); Celgene (Inst); Exelixis (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Lilly (Inst); Merck (Inst); Rain Therapeutics (Inst); Regeneron (Inst)
 
Larry R. Corum
No Relationships to Disclose
 
Aruna C. Gowda
No Relationships to Disclose
 
Gordan Srkalovic
Speakers' Bureau - EUSA Pharma; Foundation Medicine; Johnson & Johnson; Takeda
 
Raymond U. Osarogiagbon
Stock and Other Ownership Interests - Gilead Sciences; Lilly; Pfizer
Honoraria - Biodes
Consulting or Advisory Role - American Cancer Society; Association of Community Cancer Centers (ACCC); AstraZeneca; Triptych Health Partners
Patents, Royalties, Other Intellectual Property - 2 US and 1 China patents for lymph node specimen collection kit and method of pathologic evaluation.
Other Relationship - Oncobox
 
Megan Ann Baumgart
Consulting or Advisory Role - Bristol-Myers Squibb; EMD Serono
 
Lu Qian
No Relationships to Disclose
 
Katherine Minichiello
No Relationships to Disclose
 
David R. Gandara
Honoraria - AstraZeneca; CBPartners; MJH Life Sciences
Consulting or Advisory Role - Amgen; AstraZeneca (Inst); Boehringer Ingelheim; Guardant Health (Inst); Inivata; IO Biotech (Inst); Lilly (Inst); Merck; OncoCyte (Inst); Roche/Genentech
Research Funding - Amgen (Inst); Merck (Inst); Roche/Genentech (Inst)
Travel, Accommodations, Expenses - Boehringer Ingelheim
 
Roy S. Herbst
Leadership - Junshi Pharmaceuticals
Consulting or Advisory Role - Abbvie; ARMO Biosciences; AstraZeneca; Biodesix; Bolt Biotherapeutics; Bristol-Myers Squibb?; Candel Therapeutics; Cybrexa Therapeutics; eFFECTOR Therapeutics; EMD Serono; Genentech/Roche; Genmab; Halozyme; Heat Biologics; I-Mab; Immunocore; Infinity Pharmaceuticals; Junshi Pharmaceuticals; Lilly; Loxo; Merck; Mirati Therapeutics; Nektar; Neon Therapeutics; NextCure; Novartis; Oncternal Therapeutics; Pfizer; Sanofi; Seagen; Shire; Spectrum Pharmaceuticals; STCube Pharmaceuticals Inc.; Symphogen; Takeda; TESARO; Tocagen; WindMIL; Xencor
Research Funding - AstraZeneca; Genentech/Roche; Lilly; Merck
 
Karen Kelly
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; Bristol-Myers Squibb; Daiichi Sanko; Debiopharm Group; EMD Serono; EMD Serono; Genentech; Genmab; GlaxoSmithKline; Inivata; Janssen; Lilly; Novartis; Novartis; Regeneron; Symphogen; Takeda; Targeted Oncology
Research Funding - Abbvie (Inst); Amgen (Inst); Astellas Pharma (Inst); EMD Serono (Inst); Five Prime Therapeutics (Inst); Genentech (Inst); Lilly (Inst); Novartis (Inst); Regeneron (Inst); Tizona Therapeutics, Inc. (Inst)
Patents, Royalties, Other Intellectual Property - Author Royalties for UpToDate, an evidence based, peer reviewed information resource, available via the web, desktop, and PDA.
Travel, Accommodations, Expenses - Abbvie; AstraZeneca; EMD Serono; Genentech/Roche; Lilly; Merck; Regeneron